Despite remarkable advancements in pixel-level medical image perception, existing methods are either limited to specific tasks or heavily rely on accurate bounding boxes or text labels as input prompts. However, the medical knowledge required for input is a huge obstacle for general public, which greatly reduces the universality of these methods. Compared with these domain-specialized auxiliary information, general users tend to rely on oral queries that require logical reasoning. In this paper, we introduce a novel medical vision task: Medical Reasoning Segmentation and Detection (MedSD), which aims to comprehend implicit queries about medical images and generate the corresponding segmentation mask and bounding box for the target object. To accomplish this task, we first introduce a Multi-perspective, Logic-driven Medical Reasoning Segmentation and Detection (MLMR-SD) dataset, which encompasses a substantial collection of medical entity targets along with their corresponding reasoning. Furthermore, we propose MediSee, an effective baseline model designed for medical reasoning segmentation and detection. The experimental results indicate that the proposed method can effectively address MedSD with implicit colloquial queries and outperform traditional medical referring segmentation methods.

Cerebral Microbleeds (CMBs), typically captured as hypointensities from susceptibility-weighted imaging (SWI), are particularly important for the study of dementia, cerebrovascular disease, and normal aging. Recent studies on COVID-19 have shown an increase in CMBs of coronavirus cases. Automatic detection of CMBs is challenging due to the small size and amount of CMBs making the classes highly imbalanced, lack of publicly available annotated data, and similarity with CMB mimics such as calcifications, irons, and veins. Hence, the existing deep learning methods are mostly trained on very limited research data and fail to generalize to unseen data with high variability and cannot be used in clinical setups. To this end, we propose an efficient 3D deep learning framework that is actively trained on multi-domain data. Two public datasets assigned for normal aging, stroke, and Alzheimer's disease analysis as well as an in-house dataset for COVID-19 assessment are used to train and evaluate the models. The obtained results show that the proposed method is robust to low-resolution images and achieves 78% recall and 80% precision on the entire test set with an average false positive of 1.6 per scan.

Simultaneous segmentation and detection of liver tumors (hemangioma and hepatocellular carcinoma (HCC)) by using multi-modality non-contrast magnetic resonance imaging (NCMRI) are crucial for the clinical diagnosis. However, it is still a challenging task due to: (1) the HCC information on NCMRI is invisible or insufficient makes extraction of liver tumors feature difficult; (2) diverse imaging characteristics in multi-modality NCMRI causes feature fusion and selection difficult; (3) no specific information between hemangioma and HCC on NCMRI cause liver tumors detection difficult. In this study, we propose a united adversarial learning framework (UAL) for simultaneous liver tumors segmentation and detection using multi-modality NCMRI. The UAL first utilizes a multi-view aware encoder to extract multi-modality NCMRI information for liver tumor segmentation and detection. In this encoder, a novel edge dissimilarity feature pyramid module is designed to facilitate the complementary multi-modality feature extraction. Second, the newly designed fusion and selection channel is used to fuse the multi-modality feature and make the decision of the feature selection. Then, the proposed mechanism of coordinate sharing with padding integrates the multi-task of segmentation and detection so that it enables multi-task to perform united adversarial learning in one discriminator. Lastly, an innovative multi-phase radiomics guided discriminator exploits the clear and specific tumor information to improve the multi-task performance via the adversarial learning strategy. The UAL is validated in corresponding multi-modality NCMRI (i.e. T1FS pre-contrast MRI, T2FS MRI, and DWI) and three phases contrast-enhanced MRI of 255 clinical subjects. The experiments show that UAL has great potential in the clinical diagnosis of liver tumors.